Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

The switch between acute and persistent paramyxovirus infection caused by single amino acid substitutions in the RNA polymerase P subunit.

Young DF, Wignall-Fleming EB, Busse DC, Pickin MJ, Hankinson J, Randall EM, Tavendale A, Davison AJ, Lamont D, Tregoning JS, Goodbourn S, Randall RE.

PLoS Pathog. 2019 Feb 11;15(2):e1007561. doi: 10.1371/journal.ppat.1007561. eCollection 2019 Feb.

2.

Cortisol reactivity and depressive symptoms in pregnancy: The moderating role of perceived social support and neuroticism.

Kofman YB, Eng ZE, Busse D, Godkin S, Campos B, Sandman CA, Wing D, Yim IS.

Biol Psychol. 2019 Jan 28. pii: S0301-0511(18)30442-3. doi: 10.1016/j.biopsycho.2019.01.016. [Epub ahead of print]

PMID:
30703466
3.

Interferon-Induced Transmembrane Protein 1 Restricts Replication of Viruses That Enter Cells via the Plasma Membrane.

Smith SE, Busse DC, Binter S, Weston S, Diaz Soria C, Laksono BM, Clare S, Van Nieuwkoop S, Van den Hoogen BG, Clement M, Marsden M, Humphreys IR, Marsh M, de Swart RL, Wash RS, Tregoning JS, Kellam P.

J Virol. 2019 Mar 5;93(6). pii: e02003-18. doi: 10.1128/JVI.02003-18. Print 2019 Mar 15.

4.

REVEAL risk score in patients with chronic thromboembolic pulmonary hypertension receiving riociguat.

Benza RL, Farber HW, Frost A, Grünig E, Hoeper MM, Busse D, Meier C, Nikkho S, Ghofrani HA.

J Heart Lung Transplant. 2018 Jul;37(7):836-843. doi: 10.1016/j.healun.2018.02.015. Epub 2018 Mar 1.

5.

Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses.

Vogel AB, Lambert L, Kinnear E, Busse D, Erbar S, Reuter KC, Wicke L, Perkovic M, Beissert T, Haas H, Reece ST, Sahin U, Tregoning JS.

Mol Ther. 2018 Feb 7;26(2):446-455. doi: 10.1016/j.ymthe.2017.11.017. Epub 2017 Dec 5.

6.

REVEAL risk scores applied to riociguat-treated patients in PATENT-2: Impact of changes in risk score on survival.

Benza RL, Farber HW, Frost A, Ghofrani HA, Gómez-Sánchez MA, Langleben D, Rosenkranz S, Busse D, Meier C, Nikkho S, Hoeper MM.

J Heart Lung Transplant. 2018 Apr;37(4):513-519. doi: 10.1016/j.healun.2017.11.006. Epub 2017 Nov 11.

7.

RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors.

Hoeper MM, Simonneau G, Corris PA, Ghofrani HA, Klinger JR, Langleben D, Naeije R, Jansa P, Rosenkranz S, Scelsi L, Grünig E, Vizza CD, Chang M, Colorado P, Meier C, Busse D, Benza RL.

Eur Respir J. 2017 Sep 9;50(3). pii: 1602425. doi: 10.1183/13993003.02425-2016. Print 2017 Sep.

8.

Weekly High-dose 5-Fluorouracil as 24-hour Infusion Combined with Sodium Folinic Acid (AIO regimen) Plus Irinotecan in Second-line and Sequential Therapy of Metastatic Colorectal Cancer (CRC).

Wein A, Siebler J, Wolff K, Ostermeier N, Busse D, Hagel A, Koch F, Merx K, Neurath MF, Hofheinz RD.

Anticancer Res. 2017 Jul;37(7):3771-3779.

PMID:
28668873
9.

Social context matters: Ethnicity, discrimination and stress reactivity.

Busse D, Yim IS, Campos B.

Psychoneuroendocrinology. 2017 Sep;83:187-193. doi: 10.1016/j.psyneuen.2017.05.025. Epub 2017 May 31.

PMID:
28646798
10.

Discrimination and the HPA axis: current evidence and future directions.

Busse D, Yim IS, Campos B, Marshburn CK.

J Behav Med. 2017 Aug;40(4):539-552. doi: 10.1007/s10865-017-9830-6. Epub 2017 Feb 2. Review.

PMID:
28155003
11.

Successful Multidisciplinary Treatment with Secondary Metastatic Liver Resection after Downsizing by Palliative Second-Line Treatment of Colorectal Cancer: A Curative Option.

Wein A, Siebler J, Goertz R, Wolff K, Ostermeier N, Busse D, Kremer AE, Koch F, Hagel A, Farnbacher M, Kammerer FJ, Neurath MF, Gruetzmann R.

Case Rep Oncol. 2016 Jul 9;9(2):379-86. doi: 10.1159/000445677. eCollection 2016 May-Aug.

12.

Two olfactory receptors-OR2A4/7 and OR51B5-differentially affect epidermal proliferation and differentiation.

Tsai T, Veitinger S, Peek I, Busse D, Eckardt J, Vladimirova D, Jovancevic N, Wojcik S, Gisselmann G, Altmüller J, Ständer S, Luger T, Paus R, Cheret J, Hatt H.

Exp Dermatol. 2017 Jan;26(1):58-65. doi: 10.1111/exd.13132.

PMID:
27315375
13.

Treatment strategies for partial chronic instability of the distal syndesmosis: an arthroscopic grading scale and operative staging concept.

Colcuc C, Fischer S, Colcuc S, Busse D, Bliemel C, Neun O, Abt HP, Hoffmann R.

Arch Orthop Trauma Surg. 2016 Feb;136(2):157-63. doi: 10.1007/s00402-015-2371-y. Epub 2015 Dec 8.

PMID:
26646848
14.

Assessment Of Patient-Reported Health Status In Pulmonary Arterial Hypertension Patients Treated With Riociguat: 2-Year Results From The Patent-2 Extension Study.

Mathai SC, Bonner N, Minai OA, Busse D, Brockmann B, Teal S, Gater A, de la Orden Abad M.

Value Health. 2015 Nov;18(7):A398. doi: 10.1016/j.jval.2015.09.910. Epub 2015 Oct 20. No abstract available.

15.

Assessment Of Patient-Reported Health Status In Chronic Thromboembolic Pulmonary Arterial Hypertension Patients Treated With Riociguat: 2-Year Results From The Chest-2 Extension Study.

Minai OA, Bonner N, Mathai SC, Busse D, Brockmann B, Teal S, Gater A, de la Orden Abad M.

Value Health. 2015 Nov;18(7):A398-9. doi: 10.1016/j.jval.2015.09.911. Epub 2015 Oct 20. No abstract available.

16.

The effect of guided relaxation on cortisol and affect: Stress reactivity as a moderator.

Unger CA, Busse D, Yim IS.

J Health Psychol. 2017 Jan;22(1):29-38. doi: 10.1177/1359105315595118. Epub 2016 Jul 10.

PMID:
26246040
17.

Sources of dynamic variability in NF-κB signal transduction: a mechanistic model.

Mothes J, Busse D, Kofahl B, Wolf J.

Bioessays. 2015 Apr;37(4):452-62. doi: 10.1002/bies.201400113. Epub 2015 Jan 30.

18.

Silver resistance in Gram-negative bacteria: a dissection of endogenous and exogenous mechanisms.

Randall CP, Gupta A, Jackson N, Busse D, O'Neill AJ.

J Antimicrob Chemother. 2015 Apr;70(4):1037-46. doi: 10.1093/jac/dku523. Epub 2015 Jan 6.

19.

Are the costs of neuroticism inevitable? Evidence of attenuated effects in U.S. Latinas.

Campos B, Busse D, Yim IS, Dayan A, Chevez L, Schoebi D.

Cultur Divers Ethnic Minor Psychol. 2014 Jul;20(3):430-40. doi: 10.1037/a0035329.

20.

A synthetic sandalwood odorant induces wound-healing processes in human keratinocytes via the olfactory receptor OR2AT4.

Busse D, Kudella P, Grüning NM, Gisselmann G, Ständer S, Luger T, Jacobsen F, Steinsträßer L, Paus R, Gkogkolou P, Böhm M, Hatt H, Benecke H.

J Invest Dermatol. 2014 Nov;134(11):2823-2832. doi: 10.1038/jid.2014.273. Epub 2014 Jul 7.

21.

Chemosensory information processing between keratinocytes and trigeminal neurons.

Sondersorg AC, Busse D, Kyereme J, Rothermel M, Neufang G, Gisselmann G, Hatt H, Conrad H.

J Biol Chem. 2014 Jun 20;289(25):17529-40. doi: 10.1074/jbc.M113.499699. Epub 2014 May 1.

22.

Synthesis and degradation jointly determine the responsiveness of the cellular proteome.

Schwanhäusser B, Wolf J, Selbach M, Busse D.

Bioessays. 2013 Jul;35(7):597-601. doi: 10.1002/bies.201300017. Epub 2013 May 22.

PMID:
23696377
23.

Corrigendum: Global quantification of mammalian gene expression control.

Schwanhäusser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J, Chen W, Selbach M.

Nature. 2013 Mar 7;495(7439):126-7. doi: 10.1038/nature11848. Epub 2013 Feb 13. No abstract available.

PMID:
23407496
24.

Emission switching of 4,6-diphenylpyrimidones: solvent and solid state effects.

Adjaye-Mensah E, Gonzalez WG, Bussé DR, Captain B, Miksovska J, Wilson JN.

J Phys Chem A. 2012 Aug 30;116(34):8671-7. doi: 10.1021/jp3036956. Epub 2012 Aug 17.

PMID:
22856457
25.

Global quantification of mammalian gene expression control.

Schwanhäusser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J, Chen W, Selbach M.

Nature. 2011 May 19;473(7347):337-42. doi: 10.1038/nature10098. Erratum in: Nature. 2013 Mar 7;495(7439):126-7.

PMID:
21593866
26.

Palliative first-line therapy with weekly high-dose 5-fluorouracil and sodium folinic acid as a 24-hour infusion (AIO regimen) combined with weekly irinotecan in patients with metastatic adenocarcinoma of the stomach or esophagogastric junction followed by secondary metastatic resection after downsizing.

Koucky K, Wein A, Konturek PC, Albrecht H, Reulbach U, Männlein G, Wolff K, Ostermeier N, Busse D, Golcher H, Schildberg C, Janka R, Hohenberger W, Hahn EG, Siebler J, Neurath MF, Boxberger F.

Med Sci Monit. 2011 May;17(5):CR248-58.

27.

Competing feedback loops shape IL-2 signaling between helper and regulatory T lymphocytes in cellular microenvironments.

Busse D, de la Rosa M, Hobiger K, Thurley K, Flossdorf M, Scheffold A, Höfer T.

Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):3058-63. doi: 10.1073/pnas.0812851107. Epub 2010 Jan 28.

28.

The accuracy of risk assessment instruments in the prediction of impulsive versus predatory aggression.

McDermott BE, Quanbeck CD, Busse D, Yastro K, Scott CL.

Behav Sci Law. 2008;26(6):759-77. doi: 10.1002/bsl.842.

PMID:
19039802
29.

The conditional release of insanity acquittees: three decades of decision-making.

McDermott BE, Scott CL, Busse D, Andrade F, Zozaya M, Quanbeck CD.

J Am Acad Psychiatry Law. 2008;36(3):329-36.

PMID:
18802180
30.

Regeneration of meniscus cartilage in a knee treated with percutaneously implanted autologous mesenchymal stem cells.

Centeno CJ, Busse D, Kisiday J, Keohan C, Freeman M, Karli D.

Med Hypotheses. 2008 Dec;71(6):900-8. doi: 10.1016/j.mehy.2008.06.042. Epub 2008 Sep 10.

PMID:
18786777
31.

Increased knee cartilage volume in degenerative joint disease using percutaneously implanted, autologous mesenchymal stem cells.

Centeno CJ, Busse D, Kisiday J, Keohan C, Freeman M, Karli D.

Pain Physician. 2008 May-Jun;11(3):343-53.

32.

Long-lived virus-reactive memory T cells generated from purified cytokine-secreting T helper type 1 and type 2 effectors.

Löhning M, Hegazy AN, Pinschewer DD, Busse D, Lang KS, Höfer T, Radbruch A, Zinkernagel RM, Hengartner H.

J Exp Med. 2008 Jan 21;205(1):53-61. doi: 10.1084/jem.20071855. Epub 2008 Jan 14.

33.

Examining the role of static and dynamic risk factors in the prediction of inpatient violence: variable- and person-focused analyses.

McDermott BE, Edens JF, Quanbeck CD, Busse D, Scott CL.

Law Hum Behav. 2008 Aug;32(4):325-38. Epub 2007 Jun 28.

PMID:
17597388
34.

Population pharmacokinetics of the BEACOPP polychemotherapy regimen in Hodgkin's lymphoma and its effect on myelotoxicity.

Wilde S, Jetter A, Rietbrock S, Kasel D, Engert A, Josting A, Klimm B, Hempel G, Reif S, Jaehde U, Merkel U, Busse D, Schwab M, Diehl V, Fuhr U.

Clin Pharmacokinet. 2007;46(4):319-33.

PMID:
17375983
35.

Cardiovascular effects of (R)- and (S)-verapamil and racemic verapamil in humans: a placebo-controlled study.

Busse D, Templin S, Mikus G, Schwab M, Hofmann U, Eichelbaum M, Kivistö KT.

Eur J Clin Pharmacol. 2006 Aug;62(8):613-9. Epub 2006 Jul 4.

PMID:
16823584
36.

Bis(phosphine imide)s: easily tunable organic electron donors.

Guidi VV, Jin Z, Busse D, Euler WB, Lucht BL.

J Org Chem. 2005 Sep 16;70(19):7737-43.

PMID:
16149807
37.

Population pharmacokinetics of cyclophosphamide, doxorubicin and etoposide in 30 patients with BEACOPP chemotherapy.

Wilde S, Jetter A, Zaigier M, Rietbrock S, Menzel H, Sieber M, Tesch H, Hempel G, Busse D, Schwab M, Reif S, Jaehde U, Diehl V, Fuhr U.

Int J Clin Pharmacol Ther. 2002 Dec;40(12):586-8. No abstract available.

PMID:
12503825
38.

Pharmacokinetics of intravenous etoposide in patients with breast cancer: influence of dose escalation and cyclophosphamide and doxorubicin coadministration.

Busse D, Würthwein G, Hinske C, Hempel G, Fromm MF, Eichelbaum M, Kroemer HK, Busch FW.

Naunyn Schmiedebergs Arch Pharmacol. 2002 Sep;366(3):218-25. Epub 2002 Jul 3.

PMID:
12172704
39.

Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency.

Haubitz M, Bohnenstengel F, Brunkhorst R, Schwab M, Hofmann U, Busse D.

Kidney Int. 2002 Apr;61(4):1495-501.

40.

Tyrosine kinase inhibitors: rationale, mechanisms of action, and implications for drug resistance.

Busse D, Yakes FM, Lenferink AE, Arteaga CL.

Semin Oncol. 2001 Oct;28(5 Suppl 16):47-55. Review.

PMID:
11706396
41.

ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways.

Lenferink AE, Busse D, Flanagan WM, Yakes FM, Arteaga CL.

Cancer Res. 2001 Sep 1;61(17):6583-91.

42.

Disposition and pharmacologic effects of R/S-verapamil in patients with chronic atrial fibrillation: an investigation comparing single and multiple dosing.

Busse D, Fromm MF, Mörike K, Drescher S, Kühlkamp V, Eichelbaum M.

Clin Pharmacol Ther. 2001 May;69(5):324-32.

PMID:
11372000
43.

HER-2/neu (erbB-2) and the cell cycle.

Busse D, Doughty RS, Arteaga CL.

Semin Oncol. 2000 Dec;27(6 Suppl 11):3-8; discussion 92-100. Review.

PMID:
11236025
44.

Classification and analysis of incidents in complex medical environments.

Busse DK, Wright DJ.

Top Health Inf Manage. 2000 May;20(4):1-11.

PMID:
10977138
45.

Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity.

Busse D, Doughty RS, Ramsey TT, Russell WE, Price JO, Flanagan WM, Shawver LK, Arteaga CL.

J Biol Chem. 2000 Mar 10;275(10):6987-95.

46.

Fractionated administration of high-dose cyclophosphamide: influence on dose-dependent changes in pharmacokinetics and metabolism.

Busse D, Busch FW, Schweizer E, Bohnenstengel F, Eichelbaum M, Fischer P, Schumacher K, Aulitzky WE, Kroemer HK.

Cancer Chemother Pharmacol. 1999;43(3):263-8.

PMID:
9923558
47.

[Treatment of cancer with cytostatics: results with high dose therapy with cyclophosphamide and drug targeting with doxorubicin].

Busse D, Kroemer HK, Sperker B, Mürdter TE.

Pharm Unserer Zeit. 1998 Sep;27(5):216-22. Review. German. No abstract available.

PMID:
9800467
48.

Gut wall metabolism of verapamil in older people: effects of rifampicin-mediated enzyme induction.

Fromm MF, Dilger K, Busse D, Kroemer HK, Eichelbaum M, Klotz U.

Br J Clin Pharmacol. 1998 Mar;45(3):247-55.

49.

Dose escalation of cyclophosphamide in patients with breast cancer: consequences for pharmacokinetics and metabolism.

Busse D, Busch FW, Bohnenstengel F, Eichelbaum M, Fischer P, Opalinska J, Schumacher K, Schweizer E, Kroemer HK.

J Clin Oncol. 1997 May;15(5):1885-96.

PMID:
9164199
50.

Dose-dependency of oxazaphosphorine pharmacokinetics.

Busse D, Kroemer HK.

Int J Clin Pharmacol Ther. 1997 Feb;35(2):71-2. No abstract available.

PMID:
9147711

Supplemental Content

Support Center